Please login to the form below
tuberculosis
This page shows the latest tuberculosis news and features for those working in and with pharma, biotech and healthcare.
UK scientists begin testing BCG vaccine for severe COVID-19 protection
The BCG vaccine, originally developed in 1921, is traditionally used to protect against tuberculosis although it is no longer routinely administered in the UK.
Latest news
-
Researchers discover new antibiotic using AI
That included showing efficacy against tuberculosis and strains of bacteria which are considered untreatable or resistant to currently approved antibiotics.
-
GSK licenses its tuberculosis vaccine to Gates MRI
Vaccine has demonstrated around 50% efficacy in preventing disease. GlaxoSmithKline is out in front among efforts to develop a new vaccine against tuberculosis, but has decided it won’t take the
-
Antibiotic biotech Melinta files for bankruptcy
Certain infections, such as pneumonia, tuberculosis, blood poisoning, gonorrhoea and others are becoming resistant to standard antibiotics, making them increasingly hard-to-treat.
-
The NHS is facing shortages of lifesaving treatments, says internal document
In addition to identifying these new drug shortages, the document also revealed ongoing issues with 69 different types and doses of medication including antibiotics for tuberculosis, diamorphine, various cancer drugs, heart
-
GSK's pivotal TB vaccine could prevent millions of deaths
GlaxoSmithKline has announced that its IAVI-partnered experimental tuberculosis (TB) vaccine candidate significantly reduced the occurrence of pulmonary tuberculosis disease. . ... These final results show that M72/AS01E could be an important tool in
Researchers discover new antibiotic using AI
GSK licenses its tuberculosis vaccine to Gates MRI
Antibiotic biotech Melinta files for bankruptcy
The NHS is facing shortages of lifesaving treatments, says internal document
GSK's pivotal TB vaccine could prevent millions of deaths
More from news
Approximately 19 fully matching, plus 112 partially matching documents found.
Latest Intelligence
-
The need for automation in healthcare
With the NHS left with a huge backlog due to COVID-19 and illnesses such as respiratory tract infections, diarrhoeal diseases, malaria and tuberculosis representing over 90% of deaths in the
-
How will COVID-19 affect uptake of vaccinations against other diseases?
BCG, widely used for childhood immunisation against tuberculosis, has been particularly affected due to experimental use as a treatment for COVID-19.
-
Risks, reforms and rewards: the evolving Russian healthcare market
Tuberculosis and Malaria.
-
COVID-19 hits supply chains
An FDA study found that at least three WHOdesignated ‘essential medicines’ are made from APIs sourced only in China: capreomycin and streptomycin, both used to treat tuberculosis; and sulfadiazine, used to
-
Biotech profile: Tom Evans, CEO, Vaccitech.
In September 2010 he joined Aeras, a non-profit Product Development Partnership with a mission to develop global tuberculosis vaccines, as the Chief Scientific Officer, and became CEO in February 2013.
The need for automation in healthcare
How will COVID-19 affect uptake of vaccinations against other diseases?
Risks, reforms and rewards: the evolving Russian healthcare market
COVID-19 hits supply chains
More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest appointments
-
Former Merck & Co exec to lead Seres
In total Dr Pomerantz has been involved with the development of eight approved drugs for infectious diseases, covering HIV, hepatitis C and tuberculosis.
-
GlycoVaxyn appoints Gerd Zettlmeissl as chairman
He currently serves on the boards of several biotechnology companies including Aeras, an organisation dedicated to the development of tuberculosis vaccines.
-
Former PEPFAR head Mark Dybul to lead the Global Fund
Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation. ... The Global Fund to Fight AIDS, Tuberculosis and Malaria has appointed renowned AIDS expert Dr Mark Dybul as executive director.
Former Merck & Co exec to lead Seres
GlycoVaxyn appoints Gerd Zettlmeissl as chairman
Former PEPFAR head Mark Dybul to lead the Global Fund
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Antibiotic resistance: The silent pandemic
The impact. An increasing number of common infections such as pneumonia, tuberculosis, gonorrhoea and salmonellosis are becoming harder to treat as antibiotics become less effective. ... The global statistics. 123 countries report extensive multi-drug
-
World AIDS Day 2018: Fighting the stigma surrounding HIV
2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how
-
Could ketamine be the next big thing in depression?
Doctors noticed that tuberculosis patients treated with isoniazid showed signs of improved mood.
-
Exploring MINT: Part 4 - Turkey
due to migration to the urban centres of the west. In Eastern Turkey, outbreaks of communicable diseases such as tuberculosis are still occurring. Pharma investment therefore remains focused on the western
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
